[The treatment of ankylosing spondylitis with auranofin (Ridaura)].
Auranofin has no influence on axial skeleton manifestation of ankylosing spondylitis, neither on clinical complaints, nor on function and inflammatory parameters. Peripheral arthritis is possibly influenced positively, but this cannot be stated definitely because of the low number of cases in this study. This question must be analyzed in larger collectives, as alternatives to conventional therapy are needed for the treatment of peripheral joint involvement of ankylosing spondylitis.
Medizinische Klinik, Universitätskrankenhaus Hamburg-Eppendorf.
K
K
Grasedyck
M
M
Schattenkirchner
K
K
Bandilla
D001310:Auranofin / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D016037:Single-Blind Method; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*
D001310:Auranofin
Zur Behandlung der Spondylitis ankylosans mit Auranofin (Ridaura).